Goat's Rue and the Origin of Metformin
Goat's rue is the common name of Galega officinalis, a European herb also called French lilac. It was a traditional plant treatment for symptoms ascribed to diabetes, and the study of its guanidine compounds led chemists to the family of drugs that includes metformin. The plant and the drug are different things. Metformin is a single synthesised compound given in a measured amount. Goat's rue is a plant whose content varies, and veterinary records document that it has killed sheep.
Evidence base: for blood sugar in people, none. The research records behind this page hold no trial of goat's rue in people with diabetes. They hold history papers on metformin, blood sugar experiments in rats and mice, a laboratory study of how galegine acts, four veterinary reports of poisoning in sheep, and a small group of studies on a separate claim, that the plant increases breast milk.
Table of Contents
- What Goat's Rue Is
- How a Folk Remedy Led to Metformin
- What Galegine and Guanidine Do
- What Human Studies Found
- What Animal and Laboratory Studies Found
- Toxicity and Safety Findings
- How the Plant and the Drug Differ
- Other Traditional Uses: Breast Milk
- Limits of the Evidence
- Key Research Papers
- Connections
- Featured Videos
What Goat's Rue Is
Galega officinalis is a perennial herb of the Fabaceae family, the family of peas and beans. A 2021 paper that mapped the plant's chloroplast genome describes its flowers as colorful and suited to ornamental use, and states that the plant can be used as a food complement for animals and humans and could promote lactation, the production of milk (PMID 33763542). That paper was a genetics study. It did not test either use.
The research literature also calls the plant French lilac and, in one veterinary report, French honeysuckle.
A historical overview of metformin describes goat's rue as a traditional herbal medicine in Europe (PMID 28776081). A 2024 review by the same author states that metformin "can claim its origins in the use of Galega officinalis as a plant treatment for symptoms ascribed to diabetes" (PMID 38784991). Neither abstract says how the plant was prepared, how much was taken, or how well it worked.
The plant was introduced from Europe to North America. A 1986 veterinary study reported it growing in abundance in northern Utah (PMID 3750812), and a 1992 paper by the same research group called it "a known poisonous plant" with a very limited distribution in the United States (PMID 1573558).
How a Folk Remedy Led to Metformin
The steps below come from one source, a 2017 historical overview of metformin published in a diabetes journal (PMID 28776081).
From the Plant to Guanidine
According to the overview, goat's rue was found to be rich in guanidine, a small nitrogen-containing compound, and in 1918 guanidine was shown to lower blood glucose. The abstract does not say in which species that was shown.
Chemists then made guanidine derivatives, compounds built on the guanidine structure. Metformin was one of them. Some of these derivatives, though not metformin, were used to treat diabetes in the 1920s and 1930s. The overview states that they were discontinued because of toxicity and because insulin had become more widely available.
Metformin Found a Second Time
Metformin was rediscovered in the 1940s during the search for antimalarial agents. In clinical tests it proved useful to treat influenza, and in those tests it sometimes lowered blood glucose. The French physician Jean Sterne pursued that property and first reported the use of metformin to treat diabetes in 1957.
Metformin then received limited attention, the overview reports, because it was less potent than two other glucose-lowering biguanides, phenformin and buformin. Those two drugs were generally discontinued in the late 1970s because of a high risk of lactic acidosis, a dangerous build-up of lactic acid in the blood. Metformin's reputation suffered by association, "despite evident differences".
Metformin was introduced into the United States in 1995 after what the overview calls intensive scrutiny. In 1998 the United Kingdom Prospective Diabetes Study identified long-term cardiovascular benefits. Sixty years after its introduction, the overview states, metformin had become the most prescribed glucose-lowering medicine worldwide.
A 2011 review of how the body handles metformin gives the link in one line: metformin is "a biguanide developed from galegine, a guanidine derivative found in Galega officinalis" (PMID 21241070).
What Galegine and Guanidine Do
Three related names appear in this story, and they are easy to confuse.
- Guanidine is a small nitrogen-containing compound. The plant is rich in it (PMID 28776081).
- Galegine is a guanidine derivative found in the plant (PMID 21241070).
- Biguanides are a drug family built from two guanidine units joined together. Metformin (dimethylbiguanide), phenformin and buformin are biguanides.
Metformin itself is not in the plant. The 2013 food chemistry paper states that, despite their plant origin, biguanides have not been reported in plants (PMID 23411283). A person who takes goat's rue is taking guanidine and galegine, along with everything else in the plant. That person is not taking metformin.
How Galegine Acts in Laboratory and Animal Experiments
A 2022 study, indexed in PubMed as animal work and carried out in laboratory preparations and in live animals, compared metformin, phenformin and galegine. Its abstract states that the way metformin lowers blood glucose "has remained elusive". The researchers reported that all three compounds inhibit complex IV, one of the units that mitochondria (the energy-producing parts of a cell) use to make energy, and that they did so at clinically relevant concentrations. The result, they reported, was that the liver made less new glucose from glycerol, a substance released when fat is broken down (PMID 35238637).
This is a laboratory and animal finding. It does not show what goat's rue does to blood sugar in a person.
The Same Compound Is Linked to the Poisoning
The 1992 veterinary paper describes galegine as "a guanidine compound believed to be responsible" for the toxic effects of the plant in sheep, and measured it at an average concentration of about 0.46% in the goat's rue it tested (PMID 1573558). The deaths are described under Toxicity and Safety Findings.
What Human Studies Found
For blood sugar, the records behind this page hold no human study of goat's rue. PubMed was searched for the plant by its Latin name, for galegine, for the plant's toxicity, for the origins of metformin and for the plant's use in breastfeeding. None of the records found is a trial of goat's rue, or of galegine, in people with diabetes or prediabetes. No record reports the plant's effect on fasting glucose or on hemoglobin A1C (HbA1c), the blood test that reflects average blood sugar over the preceding months, in a person.
The human records fall into three groups, and none of them tests the herb for diabetes:
- Records about metformin. These concern the drug, not the plant. Trial results for metformin do not transfer to goat's rue, because metformin is not in the plant.
- The historical record of guanidine derivatives. Some were used to treat diabetes in the 1920s and 1930s and were discontinued because of toxicity and the increased availability of insulin (PMID 28776081). These were synthesised compounds given to patients. The abstract gives no numbers for their effect or for the harm they caused.
- Records about breast milk. These are described under Other Traditional Uses: Breast Milk. Their abstracts report no measurement of blood sugar.
The authors of the animal experiments describe the same gap in their own words. The 2024 mouse study ends by stating that further research is warranted to "translate these findings into clinical applications" (PMID 39139975), and the 2021 rat study presents the plant as a prospect for creating antidiabetic medicines, not as one already tested in patients (PMID 34572994).
Because no human trial was found, this page has no section on amounts used in trials. There are none to report.
What Animal and Laboratory Studies Found
Every blood sugar finding in this section comes from rats or mice. None of it was found in people.
A Rat Study of an Extract Without Alkaloids
A 2021 study gave rats with experimental diabetes an extract of the above-ground part of goat's rue that the researchers describe as devoid of alkaloids, a class of nitrogen-containing plant compounds. At a dose of 600 mg/kg (milligrams of extract per kilogram of body weight), the abstract reports a decrease in blood glucose and in glycosylated hemoglobin, better glucose tolerance, and higher C-peptide and insulin in the rats' blood plasma. C-peptide is released together with insulin and is used as a marker of how much insulin the body is making (PMID 34572994).
At 1200 mg/kg the researchers reported a protective effect on the pancreas. Compared with untreated diabetic animals, treated rats had more islets of Langerhans (the clusters of pancreas cells that make insulin), larger islets, and more beta cells, the cells within the islets that release insulin. The abstract gives no figures for the size of any of these changes. In the same study the extract showed moderate antioxidant activity in laboratory tests.
A Mouse Study That Compared an Extract With Metformin
A 2024 study was mainly about farming. Goat's rue plants were sprayed with chitosan or with salicylic acid, and the researchers measured how the sprays changed the plants. Plants sprayed with 3 millimolar salicylic acid had the highest total alkaloid content. In a separate experiment, diabetic mice given the extract from those plants at 50 mg/kg had significantly greater reductions in blood glucose than mice given metformin, an amount the abstract states as 500 mg (PMID 39139975).
The abstract does not give the number of mice, the size of the glucose change or the length of the experiment. It is a result in diabetic mice from one laboratory. No record behind this page compares goat's rue with metformin in people.
The study also shows that what is inside the plant is not fixed. The alkaloid content changed with how the plants were grown and treated.
What These Studies Do Not Show
Neither abstract reports whether the animals were harmed by the extract, and neither mentions the lung and chest effects that the sheep studies describe. A lower glucose reading in a diabetic rat or mouse does not show that a person can take the plant safely.
Toxicity and Safety Findings
Poisoning in Sheep
The four reports below are animal poisonings. They are not human data. No record behind this page describes a poisoning in a person, and none shows that the plant is safe for people.
- France, 1981 (case reports in sheep). Three cases of acute poisoning by goat's rue were recorded, described as rare. The poisoning generally occurred in summer. It took the form of an asphyxic syndrome, a failure of breathing, that led to death within hours. At post-mortem examination the animals had a voluminous hydrothorax, a large collection of fluid in the chest around the lungs. The authors wrote that the toxic mechanism was yet to be established (PMID 7336561).
- Utah, 1986 (feeding experiment in ewes). Doses as small as 0.8 g of dried plant per kg of body weight per day produced signs of poisoning: laboured breathing, lack of oxygen and a foaming discharge from the nose. Ewes that died after an overdose had severe hydrothorax, congested lungs, foamy fluid in the airways, pinpoint bleeding on the heart and, in severely affected animals, fluid around the heart. Under the microscope the lungs showed severe swelling with fluid. No significant change in blood constituents was seen in treated animals (PMID 3750812).
- 1988 (feeding experiment in ewes). Individual sheep differed widely. As little as 5 g/kg of dried ground plant caused moderate frothing in the windpipe of one ewe, while nearly 5 times that amount caused no recognizable toxic effect in others. Ten g/kg caused severe effects in 3 ewes. Between 5 and 24 g/kg, the severity of the effect was often unrelated to the amount given (PMID 3188360).
- 1992 (feeding experiment in sheep). A second plant that contains galegine, Verbesina encelioides, produced signs and lesions identical to those of goat's rue. Galegine was measured at about 0.46% in the goat's rue and 0.08% in the Verbesina collection that caused poisoning (PMID 1573558).
The 1986 study reported that ewes given the plant on several days in a row seemed to adapt and could then tolerate 5 to 10 times the earlier lethal dose. The 1988 study by the same group tested this directly and did not confirm it. Ewes with a recent history of rising doses were affected as severely by a challenge dose of 24 g/kg as ewes that had never eaten the plant. The researchers concluded that the apparent adaptation was more likely the result of extreme variation between individual animals.
Two points stand out in these reports. The harmful amount could not be predicted from one animal to the next. And the damage was to the lungs and chest, while the 1986 study saw no significant change in blood constituents.
The Drug Family's Record in People
Guanidine derivatives used for diabetes in the 1920s and 1930s were discontinued because of toxicity. Phenformin and buformin were generally discontinued in the late 1970s because of a high risk of lactic acidosis (PMID 28776081). The 2011 review calls lactic acidosis "the feared adverse effect of the biguanide drugs" and states that its incidence is very low in patients treated with metformin (PMID 21241070). No record behind this page reports whether goat's rue or galegine causes lactic acidosis in people. It has not been measured in the studies found.
Safety Facts That Apply to Any Blood Sugar Herb
- Type 1 diabetes. Type 1 diabetes is a state of absolute insulin deficiency. No herb, food or diet replaces insulin. Without insulin, diabetic ketoacidosis develops, and it is fatal if untreated.
- Low blood sugar. Anything that lowers blood sugar adds to the effect of insulin and of sulfonylurea drugs. The signs of low blood sugar (hypoglycemia) are shakiness, sweating, a fast heartbeat and confusion, and at lower levels seizure or loss of consciousness. The records behind this page hold no human study that measured how goat's rue combines with any diabetes medication.
- Products differ. Herbal products vary in plant part, extract and content from one product to the next. For goat's rue, the 2024 mouse study found that total alkaloid content changed with how the plants were treated.
- Pregnancy, breastfeeding and infants. The breast milk studies described below report milk volume and feeding outcomes. Their abstracts report no laboratory safety measurements in mothers or infants, and a 2026 systematic review describes the safety of herbal milk-promoting products as unclear (PMID 41350450).
How the Plant and the Drug Differ
The table sets out what the records behind this page state about the plant and about the drug.
| Point of comparison | Goat's rue (the plant) | Metformin (the drug) |
|---|---|---|
| What it is | A perennial herb containing guanidine and galegine, among other compounds | Dimethylbiguanide, a single synthesised compound |
| Is metformin in it | No. Biguanides have not been reported in plants | Yes |
| Amount of active compound | Not fixed. Galegine averaged about 0.46% in one tested collection, and alkaloid content changed with growing conditions | A measured amount in each tablet |
| How the body handles it | No human data in the records found | Mean oral bioavailability 55 ± 16%; excreted unchanged in urine; elimination half-life approximately 5 hours with good kidney function |
| Trials in people with diabetes | None in the records found | In use for diabetes since 1957; long-term cardiovascular benefits identified in 1998 |
| Known harms | Fatal poisoning in sheep, with fluid in the chest and lungs; human safety not studied in the records found | Possible stomach and bowel side effects at the start; lactic acidosis, with very low incidence; needs adequate kidney function to be cleared |
The metformin figures come from a 2011 review of how the body absorbs and clears the drug (PMID 21241070). Bioavailability is the share of a swallowed amount that reaches the blood. Half-life is the time the body takes to clear half of the drug. The same review states that metformin clearance falls roughly in proportion to kidney function, and its authors call for the dosage to be reduced in the same proportion in patients with impaired kidneys. These records hold no such figures for goat's rue or for galegine in people.
The 2024 review of metformin states that the drug acts principally in the gut, liver and muscle to counter insulin resistance and lower blood glucose without weight gain or risk of overt hypoglycemia. It also states that metformin requires adequate kidney function for its elimination and may cause stomach and bowel side effects at the start, which are moderated by taking it with meals or by an extended-release form (PMID 38784991). These are findings about the drug. They were not shown for the plant.
Other Traditional Uses: Breast Milk
Goat's rue is also used as a galactagogue, a substance taken to increase breast milk. This is a separate claim from blood sugar. The human studies found all tested goat's rue mixed with other ingredients, so none of them shows what the plant does on its own.
A Randomized Trial of a Combined Product
A double-blind randomized controlled trial enrolled mothers of preterm infants born at 27 to 32 weeks of pregnancy. The mothers took either a product containing silymarin (an extract of milk thistle) with phosphatidylserine and galega, or a placebo, during the first month after delivery. A 2018 follow-up asked them about their milk at 3 and 6 months (PMID 29148822).
- Of the 100 mothers, 45 in the product group and 44 in the placebo group answered fully.
- At the third month, 22 mothers in the product group and 12 in the placebo group reported feeding only human milk (p < 0.05).
- 29 mothers in the product group and 18 in the placebo group were able to give more than 50% of the milk their infant took.
- At the sixth month only eight infants received only human milk, six in the product group and two in the placebo group. The authors wrote that these data were not sufficient for a meaningful clinical evaluation.
The outcomes were reported by the mothers. The product contained three ingredients, so the result cannot be assigned to goat's rue.
What the Reviews Concluded
A systematic review published in 2026 looked at randomized controlled trials of herbal galactagogues in mothers of preterm babies. It included ten trials, each of a different herb or mixture. Two were rated at high risk of bias and the rest raised "some concerns". For silymarin combined with phosphatidylserine and galega, the review found low certainty evidence of more milk by day 7, a mean difference of 105 milliliters (95% confidence interval 27 to 183). The reviewers concluded that there is a lack of high-quality randomized controlled trials and that higher-quality trials are needed to confirm the effect (PMID 41350450).
A 2012 review of galactagogues available in the United States, which searched for goat's rue by name, concluded that although a variety of herbal and pharmaceutical options have anecdotal evidence behind them, peer-reviewed studies proving their efficacy are lacking, and that efficacy and safety data in the literature are lacking (PMID 23012383). Its abstract reports no trial result for goat's rue.
A 2017 review took a more favorable view. It described Galega officinalis as among the natural remedies with the strongest evidence and commented on a food supplement containing galega together with vitamins and magnesium. Its support was a product evaluation in Italian women, in which the wide majority of mothers declared themselves satisfied and two thirds reported that milk production improved. These were the mothers' own reports. The abstract describes no comparison group and no measurement of milk, describes safety as "perceived by the participants", and itself states that further clinical trials could provide further evidence (PMID 27901335).
Limits of the Evidence
- No human trial for blood sugar. The records behind this page hold no study of goat's rue or galegine in people with diabetes. Whether the plant lowers blood sugar in people, by how much, and at what amount, is not answered by them.
- No human safety data. The toxicity records are all in sheep. They show that the plant can kill a grazing animal and that the harmful amount varied widely between animals. They do not establish a safe or a harmful amount for a person.
- The animal blood sugar studies are few and thinly reported. One rat study and one mouse study were found. Their abstracts give doses but no figures for the size of the glucose change, the number of animals or the length of treatment.
- The plant is not a standard substance. Galegine content was measured in one collection, and alkaloid content changed with growing conditions. A result for one extract does not transfer to another.
- The breast milk studies tested mixtures. No study found tested goat's rue alone, and the one pooled result was rated low certainty.
- Evidence for metformin is not evidence for goat's rue. Metformin's trial record and safety profile belong to a compound of a class that has not been reported in plants.
Key Research Papers
- Bailey CJ. Metformin: historical overview. Diabetologia. 2017;60(9):1566-1576. PubMed PMID: 28776081
- Bailey CJ. Metformin: Therapeutic profile in the treatment of type 2 diabetes. Diabetes Obes Metab. 2024;26 Suppl 3:3-19. PubMed PMID: 38784991
- Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50(2):81-98. PubMed PMID: 21241070
- Perla V, Jayanty SS. Biguanide related compounds in traditional antidiabetic functional foods. Food Chem. 2013;138(2-3):1574-80. PubMed PMID: 23411283
- LaMoia TE, Butrico GM, Kalpage HA, Goedeke L, Hubbard BT, Vatner DF, et al. Metformin, phenformin, and galegine inhibit complex IV activity and reduce glycerol-derived gluconeogenesis. Proc Natl Acad Sci U S A. 2022;119(10):e2122287119. PubMed PMID: 35238637
- Hachkova H, Nagalievska M, Soliljak Z, Kanyuka O, Kucharska AZ, Sokół-Łętowska A, et al. Medicinal Plants Galega officinalis L. and Yacon Leaves as Potential Sources of Antidiabetic Drugs. Antioxidants (Basel). 2021;10(9):1362. PubMed PMID: 34572994
- Angouti F, Nourafcan H, Saeedi Sar S, Assadi A, Ebrahimi R. Optimizing antidiabetic properties of Galega officinalis extract: Investigating the effects of foliar application of chitosan and salicylic acid. Food Sci Nutr. 2024;12(8):5844-5857. PubMed PMID: 39139975
- Puyt JD, Faliu L, Keck G, Gedfrain JC, Pinault L, Tainturier D. Fatal poisoning of sheep by Galega officinalis (French honeysuckle). Vet Hum Toxicol. 1981;23(6):410-2. PubMed PMID: 7336561
- Keeler RF, Johnson AE, Stuart LD, Evans JO. Toxicosis from and possible adaptation to Galega officinalis in sheep and the relationship to Verbesina encelioides toxicosis. Vet Hum Toxicol. 1986;28(4):309-15. PubMed PMID: 3750812
- Keeler RF, Baker DC, Evans JO. Individual animal susceptibility and its relationship to induced adaptation or tolerance in sheep to Galega officinalis L. Vet Hum Toxicol. 1988;30(5):420-3. PubMed PMID: 3188360
- Keeler RF, Baker DC, Panter KE. Concentration of galegine in Verbesina encelioides and Galega oficinalis and the toxic and pathologic effects induced by the plants. J Environ Pathol Toxicol Oncol. 1992;11(2):11-7. PubMed PMID: 1573558
- Du W, Jiang W, Yi D, Pang Y. The complete chloroplast genome of Galega officinalis L. Mitochondrial DNA B Resour. 2021;6(2):663-665. PubMed PMID: 33763542
- Serrao F, Corsello M, Romagnoli C, D'Andrea V, Zecca E. The Long-Term Efficacy of a Galactagogue Containing Sylimarin-Phosphatidylserine and Galega on Milk Production of Mothers of Preterm Infants. Breastfeed Med. 2018;13(1):67-69. PubMed PMID: 29148822
- Cragg A, Levene I, Darabi S, Willcox M. Herbal galactagogues to improve breastmilk production and lactation in mothers of preterm babies: a systematic review of clinical trials. Eur J Clin Nutr. 2026;80(2):146-158. PubMed PMID: 41350450
- Salatino S, Giacomelli L, Carnevali I, Giacomelli E. The role of natural galactagogues during breast feeding: focus on a Galega officinalis based food supplement. Minerva Pediatr. 2017;69(6):531-537. PubMed PMID: 27901335
- Forinash AB, Yancey AM, Barnes KN, Myles TD. The use of galactogogues in the breastfeeding mother. Ann Pharmacother. 2012;46(10):1392-404. PubMed PMID: 23012383